AdAlta plants its flag in China with Shanghai office approval
AdAlta Limited (ASX: 1AD) has received approval from the Shanghai Municipal Administration for Market Regulation to establish a representative office in Shanghai, China. The approval gives the clinical-stage biotechnology company an official physical presence in the country that sits at the heart of its “East to West” strategy, where the cellular immunotherapies it seeks to licence are being invented and tested.
China is the primary source of innovation for AdAlta’s business model, which in-licences Asian cellular immunotherapy assets and prepares them for Western biopharmaceutical buyers. The Shanghai office marks the company’s first physical presence in the country, enabling it to engage local staff and contractors on the ground for the first time, rather than relying on periodic visits from Australia.
When big ASX news breaks, our subscribers know first
What a representative office actually means
A representative office is an established legal form through which a foreign company sets up an official but cost-effective presence in China. For retail investors, three operational capabilities are now unlocked:
- People: AdAlta can engage local staff and contractors to represent and promote the company in China, operating in the same country, language, and time zone as its partners.
- Standing: Partners, hospitals, manufacturers, and originators deal with an official, locally recognised AdAlta presence rather than an offshore company they meet occasionally.
- Continuity: Relationships, due diligence, and technology transfer can be progressed continuously and in person, rather than in bursts around travel schedules.
Importantly, AdAlta remains Australian-domiciled and holds intellectual property rights outside greater China. Where value is created and captured by AdAlta does not change.
Strengthening the engine room of “East to West”
The representative office strengthens three things simultaneously for AdAlta:
- Management of the existing collaboration with Shanghai Cell Therapy Group Co Ltd (SHcell) for lead asset EW-001.
- Systematic scanning of the Chinese market for new in-licensing candidates.
- Establishment of further collaborations with Chinese manufacturing and development partners.
The strategic rationale for a physical China presence is significant. The country hosts more than 970 clinical trials and over 350 developers in cellular immunotherapy, making it the most active source of innovation in the field globally. Being present upstream, where products are found, is the step AdAlta’s “East to West” model depends on most.
AdAlta’s East to West commercialisation model targets an all-in investment of approximately US$15 million per asset, with the company retaining a 60% share of Phase I commercialisation event proceeds against a median comparable deal value of US$782 million across the sector.
Dr Tim Oldham, CEO & Managing Director
“China is where the cellular immunotherapies we want to license are being invented and tested, and relationships in this industry are not built over video calls alone. This approval gives AdAlta the ability, for the first time, to have its own people on the ground in China – managing our collaboration with SHcell, sitting across the table from the next generation of Chinese innovators, and building the partnerships that make our ‘East to West’ model repeatable. EW-001 is the first product to come through our model, and the representative office is how we make sure it is not the last.”
The representative office directly strengthens the upstream step in AdAlta’s pipeline sourcing process, where products are identified and relationships are initiated, in a capital-efficient manner.
EW-001 and what’s next for AdAlta
EW-001 is AdAlta’s lead asset: a novel, first-in-class CAR-T cell therapy designed to treat mesothelioma, a rare and rapidly fatal cancer typically linked to asbestos exposure, with possible application in more than ten other cancers. The therapy is partnered with SHcell and has generated early clinical results in relapsed or advanced mesothelioma patients in China that compare favourably against standard-of-care outcomes.
The CAR-T clinical results in mesothelioma that underpin AdAlta’s partnering case include two patients who achieved full tumour clearance, with one patient’s lesions remaining undetectable 18 months after a single infusion, an outcome described as highly unusual in relapsed or refractory disease.
| Metric | Standard of Care (second line) | EW-001 Clinical Results |
|---|---|---|
| Overall Response Rate | 11–29% | Up to 50% |
| Complete Response Rate | Almost never (second line) | Up to 20% |
| Median Overall Survival | 8–10 months (second line) | Not yet reached (earlier generation achieved more than 25 months) |
Note: EW-001 has not yet received regulatory approval for general commercial launch anywhere in the world. These are early clinical results from studies conducted in China.
AdAlta has indicated it will develop its China-based team in measured steps as its pipeline and partners require. For shareholders, the strategic significance is direct: AdAlta’s value is generated by repeatedly identifying excellent Asian cellular immunotherapies, securing the rights to them, and preparing them for Western biopharmaceutical buyers. The representative office approval strengthens the step furthest upstream in that process, where the products themselves are found.
Don’t Miss the Next Biotech Breakthrough Before the Market Moves
Get FREE breaking ASX healthcare and biotech news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 active subscribers rely on Big News Blast to stay ahead of market-moving announcements. Click the “Free Alerts” button to start receiving alerts the moment ASX news breaks.